Cargando…

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

Detalles Bibliográficos
Autores principales:	Liu, Zhigang, Alexander, James L., Lin, Kathy Weitung, Ahmad, Tariq, Pollock, Katrina M., Powell, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the AGA Institute 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578965/ https://www.ncbi.nlm.nih.gov/pubmed/36270334 http://dx.doi.org/10.1053/j.gastro.2022.10.010

Ejemplares similares

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
por: Liu, Zhigang, et al.
Publicado: (2023)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
por: Liu, Zhigang, et al.
Publicado: (2023)

Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2
por: Williams, Erin, et al.
Publicado: (2022)

Antibodies induced by ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1
por: Windsor, Ian W., et al.
Publicado: (2022)

Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
por: Jia, Liqiu, et al.
Publicado: (2022)

Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
por: Kantasiripitak, Wannee, et al.
Publicado: (2022)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants
por: Lusvarghi, Sabrina, et al.
Publicado: (2023)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
por: Gao, Yu, et al.
Publicado: (2022)

Increased Stability of SARS-CoV-2 Omicron Variant over Ancestral Strain
por: Chin, Alex Wing Hong, et al.
Publicado: (2022)

Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico
por: Dehesa-Canseco, Freddy, et al.
Publicado: (2023)

Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
por: Wiles, C Alex, et al.
Publicado: (2021)

Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, Delta, Omicron variants and vaccines
por: Law, Nicole, et al.
Publicado: (2022)

Novaferon Effectively Inhibits Ancestral SARS-CoV-2 and Omicron Variant in Vitro, 2022
por: Ye, Fei, et al.
Publicado: (2022)

Incidence and severity of pulmonary embolism in COVID-19 infection: Ancestral, Alpha, Delta, and Omicron variants
por: Wada, Noriaki, et al.
Publicado: (2023)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD
por: Ray, Katrina
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH
por: Vergori, Alessandra, et al.
Publicado: (2022)

Handheld NIR-to-NIR Platform for on-site evaluating protective neutralizing antibody against SARS-CoV-2 ancestral strain and Omicron variant after vaccination or infection
por: Song, Qingwei, et al.
Publicado: (2023)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Accuracy of ancestral state reconstruction for non-neutral traits
por: Holland, Barbara R., et al.
Publicado: (2020)

Post-Vaccination Neutralization Responses to Omicron Sub-Variants
por: Jacobsen, Henning, et al.
Publicado: (2022)

Neutralization, effector function and immune imprinting of Omicron variants
por: Addetia, Amin, et al.
Publicado: (2023)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant
por: Villas-Boas, Lucy Santos, et al.
Publicado: (2022)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

Omicron‐specific mRNA vaccine induced cross‐protective immunity against ancestral SARS‐CoV‐2 infection with low neutralizing antibodies
por: Shen, Kuan‐Yin, et al.
Publicado: (2022)

Tofacitinib
Publicado: (2012)

Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice
por: Verhulst, Stefaan, et al.
Publicado: (2016)

Increasing contributions of airborne route in SARS-CoV-2 omicron variant transmission compared with the ancestral strain
por: Ji, Shuyi, et al.
Publicado: (2022)

Prevalence of Pneumonia Among Patients Who Died with COVID-19 Infection in Ancestral Versus Omicron Variant Eras
por: Hammer, Mark M., et al.
Publicado: (2023)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
por: Schultz, Bárbara M., et al.
Publicado: (2022)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k339qo65khbhkei8dapkn0vk9l